TEL AVIV, Israel, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (FXS), today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI), effective upon market open on December 21, 2015.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Companies listed on the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. For more information about the NASDAQ Biotechnology Index visit www.nasdaq.com.
For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit https://indexes.nasdaqomx.com/.
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 email@example.com Media Inquiries Sam Brown, Inc. Mike Beyer 312-961-2502 firstname.lastname@example.org Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 email@example.com